Price T Rowe Associates Inc Nurix Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

  • $867 Billion
  • Q4 2024

A detailed history of Price T Rowe Associates Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,007,327 shares of NRIX stock, worth $52.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,007,327
Previous 3,068,961 2.01%
Holding current value
$52.9 Million
Previous $69 Million 17.84%
% of portfolio
0.01%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$18.64 - $28.14 $1.15 Million - $1.73 Million
-61,634 Reduced 2.01%
3,007,327 $56.7 Million
Q3 2024

Nov 14, 2024
BUY
$18.93 - $25.69 $4.43 Million - $6.01 Million
233,842 Added 8.25%
3,068,961 $69 Million
Q2 2024

Aug 14, 2024
BUY
$12.02 - $21.3 $7.68 Million - $13.6 Million
638,950 Added 29.09%
2,835,119 $59.2 Million
Q1 2024

May 15, 2024
SELL
$7.77 - $15.66 $1.51 Million - $3.03 Million
-193,797 Reduced 8.11%
2,196,169 $32.3 Million
Q4 2023

Feb 14, 2024
BUY
$4.25 - $10.71 $50,949 - $128,391
11,988 Added 0.5%
2,389,966 $24.7 Million
Q3 2023

Nov 14, 2023
SELL
$7.86 - $10.08 $14,894 - $19,101
-1,895 Reduced 0.08%
2,377,978 $18.7 Million
Q2 2023

Aug 14, 2023
SELL
$8.7 - $13.28 $1.78 Million - $2.72 Million
-204,878 Reduced 7.93%
2,379,873 $23.8 Million
Q1 2023

May 15, 2023
SELL
$8.56 - $13.26 $5.73 Million - $8.87 Million
-668,985 Reduced 20.56%
2,584,751 $23 Million
Q4 2022

Feb 14, 2023
SELL
$9.86 - $14.59 $3.48 Million - $5.14 Million
-352,616 Reduced 9.78%
3,253,736 $35.7 Million
Q3 2022

Nov 14, 2022
SELL
$12.33 - $19.81 $12.5 Million - $20.1 Million
-1,014,471 Reduced 21.95%
3,606,352 $47 Million
Q2 2022

Aug 15, 2022
SELL
$7.88 - $14.82 $1.46 Million - $2.75 Million
-185,466 Reduced 3.86%
4,620,823 $58.5 Million
Q1 2022

May 16, 2022
SELL
$12.94 - $29.65 $838,447 - $1.92 Million
-64,795 Reduced 1.33%
4,806,289 $67.3 Million
Q4 2021

Feb 14, 2022
BUY
$26.43 - $34.5 $4.02 Million - $5.25 Million
152,207 Added 3.23%
4,871,084 $141 Million
Q3 2021

Nov 15, 2021
BUY
$22.71 - $36.69 $15.2 Million - $24.5 Million
667,399 Added 16.47%
4,718,877 $141 Million
Q2 2021

Aug 16, 2021
BUY
$24.21 - $35.89 $23.2 Million - $34.4 Million
957,773 Added 30.96%
4,051,478 $107 Million
Q1 2021

May 17, 2021
BUY
$26.98 - $50.17 $67.5 Million - $126 Million
2,502,069 Added 422.91%
3,093,705 $96.2 Million
Q4 2020

Feb 16, 2021
BUY
$22.85 - $48.44 $13.5 Million - $28.7 Million
591,636 New
591,636 $19.5 Million

Others Institutions Holding NRIX

# of Institutions
184
Shares Held
70.6M
Call Options Held
318K
Put Options Held
42.4K
View Full List

About Nurix Therapeutics, Inc.

NRIX Quotes by TradingView
  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $829M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email